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Abstract
Background: The purpose of the study was to evaluate systematic reviews of research into two public health
priorities, tobacco consumption and HIV infection, in terms of the reporting of data related to the applicability of
trial results (i.e., whether the results of a trial can be reasonably applied or generalized to a definable group of
patients in a particular setting in routine practice, also called external validity or generalisability).
Methods: All systematic reviews of interventions aimed at reducing or stopping tobacco use and treating or
preventing HIV infection published in the Cochrane database of systematic reviews and in journals indexed in
MEDLINE between January 1997 and December 2007 were selected. We used a standardized data abstraction form
to extract data related to applicability in terms of the context of the trial, (country, centres, settings), participants
(recruitment, inclusion and exclusion criteria, baseline characteristics of participants such as age, sex, ethnicity,
coexisting diseases or co-morbidities, and socioeconomic status), treatment (duration, intensity/dose of treatment,
timing and delivery format), and the outcomes assessment from selected reviews.
Results: A total of 98 systematic reviews were selected (57 Cochrane reviews and 41 non-Cochrane reviews); 49
evaluated interventions aimed at reducing or stopping tobacco use and 49 treating or preventing HIV infection.
The setting of the individual studies was reported in 45 (46%) of the systematic reviews, the number of centres in
21 (21%), and the country where the trial took place in 62 (63%). Inclusion and exclusion criteria of the included
studies were reported in 16 (16%) and 13 (13%) of the reviews, respectively. Baseline characteristics of participants
in the included studies were described in 59 (60%) of the reviews. These characteristics concerned age in about
half of the reviews, sex in 46 (47%), and ethnicity in 9 (9%).
Applicability of results was discussed in 13 (13%) of the systematic reviews. The reporting was better in systematic
reviews by the Cochrane Collaboration than by non-Cochrane groups.
Conclusions: Our study highlighted the lack of consideration of applicability of results in systematic reviews of
research into 2 public health priorities: tobacco consumption and HIV infection.
Background
Systematic reviews are an important source of valid evi-
dence [1] because they identify, appraise and synthesize
all the available evidence on a particular topic [1-3].
Theoretically, systematic reviews should evaluate and
take into account the internal validity (i.e., the extent to
which systematic errors or bias are avoided) of each trial
included but also the applicability and generalizability or
external validity (i.e., whether the results of a trial can
be reasonably applied to a definable group of patients in
a particular setting in routine practice)[4]. Several meth-
odological works have been published to allow for ade-
quately understanding and assessing internal validity
[5-10]. Recently, the Cochrane Collaboration developed
as p e c i f i ct o o lt oa p p r a i s et h ei n t e r n a lv a l i d i t yo ft r i a l
results included in systematic reviews, the Risk of Bias
tool [11] and research is still being conducted in this
field[12]. In contrast, methodological research on the
applicability of trial results is still at its beginning
[13-15]. Some authors have highlighted that external
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dimensional concept [4,16]. They particularly noted that
judging the external validity of study results is complex,
consisting in prior knowledge, statistical considerations,
and eligibility criteria [4]. Other authors focused on the
reporting of applicability data to give readers sufficient
information to be able to judge the external validity and
applicability of the results of a trial [17,18]. For example,
Glasziou and colleagues addressed this issue in stating
that the description of interventions was insufficient to
allow clinicians to replicate the intervention in clinical
practice[19].
The main objective of this study was to evaluate sys-
tematic reviews of research into two public health prio-
rities, tobacco consumption and HIV infection, in terms
of the reporting of data related to the applicability of
trial results (i.e., whether the results of a trial can be
reasonably applied or generalized to a definable group
of patients in a particular setting in routine practice,
also called external validity or generalisability)[16].
A secondary objective was to compare the reporting of
data related to applicability in systematic reviews pub-
lished by the Cochrane Collaboration and other sys-
tematic reviews indexed in Medline [20].
Methods
Choice of the medical domain
We focused on 2 public health priorities: tobacco con-
sumption and HIV infection[21]. Tobacco use is a lead-
ing preventable cause of death in the world; it is
currently responsible for about 5 million deaths each
year (one person every 6 sec). By 2030, the number of
deaths will exceed 8 million a year [22,23]. The use of
tobacco is on the increase in developing countries and
among women in developed countries [22,24]. HIV/
AIDS is also one of the most urgent threats to global
public health. In 2007, the number of people living with
HIV infection worldwide was estimated at 33.2 million;
this number continues to increase, particularly in devel-
oping countries [25], where access to healthcare services
is limited [26].
Managing smoking cessation as well as treating and
preventing HIV infection relies on a combination of
pharmacological treatments and behavioural interven-
tions. The success of such treatments depends highly on
patient characteristics and socioeconomic and cultural
factors but also on the organization of healthcare.
Therefore, systematic reviews of research into both
topics must evaluate and consider the applicability of
the results of that research.
Search strategy
We identified all reports of systematic reviews of inter-
ventions aimed at reducing or stopping tobacco use and
treating or preventing HIV infection that were published
in the Cochrane database of systematic reviews and in
journals indexed in MEDLINE between January 1 1997
and December 31 2007. We systematically searched
MEDLINE for meta-analyses of articles and the
Cochrane database of systematic reviews, looking for the
following terms in the title, abstract and MeSH terms:
“smoking cessation” OR “tobacco use cessation” OR
“smoking reduction” OR “tobacco reduction” OR “smok-
ing abstinence” OR “tobacco abstinence” for tobacco use
and “HIV” OR “Human immunodeficiency virus” OR
“AIDS” OR “acquired immunodeficiency syndrome” OR
“sexually transmitted diseases” for HIV infection (see
Additional file 1).
Eligibility criteria and screening process
We collected the electronic records in an Endnote data
file. Titles and abstracts of the electronic search results
were screened by one of us (NA) to identify the relevant
studies.
Using endnote search, we systematically search for
reports having same authors, and the most recent review
was included.
From selected abstracts, the full texts of articles were
retrieved and reviewed by one of us (NA) to determine
eligibility of studies for inclusion. For practical reasons,
only one author performed the screening process. For
quality assurance, another author (IB) double-checked
the abstracts selected and the full-text articles excluded.
Reports were included if the study was identified as a
systematic review of interventions aimed at stopping or
reducing tobacco consumption or preventing or treating
HIV infections.
A systematic review was defined as a scientific process
seeking to collate all evidence that fits pre-specified elig-
ibility criteria and to minimize bias by using explicit,
systematic methods.
We excluded protocols of systematic reviews, sys-
tematic reviews focusing on a specific context (e.g.,
intervention for tobacco cessation in the dental set-
ting), or a specific population (e.g., intervention for
tobacco cessation during pregnancy or for hospitalized
patients). In fact, because we focused on the adequate
reporting of data related to the applicability of trial
results, we decided not to include reviews of trials per-
formed in a specific context or of specific patients
such as the dental setting or hospitalized patients
because evaluating the reporting of data related to the
context or patient for these trials would be difficult if
these criteria were eligibility criteria for the selected
trial. Excluding these systematic reviews also allowed
for a relatively homogeneous sample that should
include reports containing all the applicability data
domains. We also excluded systematic reviews
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of HIV infection (e.g., opportunistic infections, Kaposi’s
sarcoma), and those evaluating a treatment for another
disease among individuals with HIV infection (e.g.,
treatment of anemia in people with HIV). Overviews
such as those published by Clinical Evidence were not
selected in this study.
The systematic reviews were classified into 2 cate-
gories according to the data source: Cochrane reviews (i.
e., systematic reviews performed and published by the
Cochrane Collaboration) and non-Cochrane reviews (i.
e., systematic reviews indexed in MEDLINE and per-
formed by a non-Cochrane group).
Data collection
Characteristics of the selected reports
We collected information on the category of treatment
evaluated (i.e., pharmacological treatment such as oral
drugs and nonpharmacological treatments such as edu-
cation, quit lines or packages of care); for nonpharmaco-
logic treatment, we determined whether the treatment
was a therapist-dependent intervention (i.e., the success
of the treatment depended on care providers’ expertise
and skill such as counselling, hypnosis, or acupuncture),
the number of studies included, and the outcomes eval-
uated (e.g., for reviews of HIV infection: mortality; inci-
dence of HIV infection; plasma HIV viral load; and for
reviews of tobacco consumption: self-reported absti-
nence rate; self-reported smoking reduction rate; results
of biological tests such as saliva, urine and serum nico-
tine levels; and expired carbon monoxide level). We
checked whether a quantitative analysis (i.e., meta-analy-
sis) was performed.
We determined whether and how the internal validity
of the studies included in the systematic review was
evaluated, reported and taken into account in the analy-
sis and interpretation of the systematic review. We also
recorded whether a narrative discussion or a summary
description of the assessment of internal validity for the
included studies was available.
Data related to applicability of results
To evaluate the reporting of data related to the applic-
ability of trial results in systematic reviews, we devel-
oped a standardized data extraction form. To create this
form, we relied on articles identified through a literature
search [1,4,7,16,27-31] or known by or published by the
authors of this article[17,18,32]. We also relied on the
following reporting guidelines: the CONSORT State-
ment, the extension of the CONSORT Statement for
nonpharmacologic treatment and the PRISMA State-
ment for reporting systematic reviewsand meta-analyses
[31-33]. Our aim was not to perform a systematic
review on this topic but rather to identify items deemed
relevant. Using these articles, we generated a list of
items deemed important: context of care, participants,
intervention and outcome assessment.
Before data extraction, as a calibration exercise, the
standardized form was tested by one of us (NA) on a
separate set of 10 systematic reviews. One reviewer
(NA) completed all the data extraction. A random sam-
ple of 30 articles was reviewed for quality assurance
[34].
To evaluate the reporting of data related to applicabil-
ity of results in the systematic review, we focused on 2
issues: 1) the key data related to applicability of results
reported for each study included in the systematic
review, and 2) the data related to applicability of results
explored in the analysis and taken into account for the
interpretation of the results.
For this purpose, in a first step, we checked whether
the following data related to applicability were systema-
tically reported in the review for each study included in
the review: 1) the context of the trial: countries where
the trial took place, the number of centres (because the
applicability of a trial performed in only one centre
could be questionable), and the setting (i.e., physicians,
general medical hospital, university hospital); 2) partici-
pants: the method of recruitment (i.e., referral from phy-
sicians, self-selection of patients through advertisement),
eligibility criteria, and essential data on baseline charac-
teristics of participants (i.e., age, sex, ethnicity, coexist-
ing diseases or co-morbidities, and socio-economic
status); 3) treatment: the duration, intensity/dose of
treatment, timing, delivery format and compliance of
participants and the reporting of care providers’ qualifi-
cations or expertise for reviews focusing on therapist-
dependent interventions.
We systematically checked the systematic review’s
text, tables and appendices for descriptions of primary
studies included in the systematic reviews. We particu-
larly searched for the reporting of applicability data of
primary studies. However, these data could be inconsis-
tently reported. For example, a table describing each pri-
mary study could include the number of centres for
some primary trials, but not for others. We hypothe-
sized that this inconsistent reporting is probably related
to these data being inconsistently reported in the pub-
lished reports of primary trials. Consequently, the data
are not reported in the table probably because they are
not reported in the primary report.
We considered that if these data were reported for at
least one primary study, they were systematically
searched for by the reviewers.
In a second step, we checked whether applicability
criteria were taken into account in the review analysis
(e.g., subgroup analysis) and discussed the interpretation
of the results as recommended by the PRISMA state-
ment[35].
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whereas partial reporting was classified as being
reported.
Statistical analysis
We used descriptive statistics; categorical variables were
described with frequencies and percentages and quanti-
tative variables with mean (SD). All data analysis
involved use of SAS for Windows, Release 9.1 (SAS
Institute, Cary, NC).
The data set is available in Additional file 2.
Results
Articles selected
The flow of articles through the study is in Figure 1 and
characteristics of the included systematic reviews are in
Table 1. A total of 98 reviews were selected for the final
analysis. The treatment evaluated concerned nonphar-
macologic treatments in nearly two-thirds (n = 59) of
the reports. The intervention evaluated was a therapist-
dependent intervention in 45 (46%) reviews. Quantita-
tive analyses were performed in 79 (81%) of the sys-
tematic reviews. In the field of tobacco use, 42 (86%) of
the systematic reviews selected only randomised con-
trolled trials, whereas in the field of HIV infection, more
than half of the systematic reviews selected only rando-
mised controlled trials. For reviews of tobacco use, the
outcome of the review was abstinence in 37 (75%)
reports. For those of HIV, 22 (44%) had at least one
clinically relevant primary outcome (e.g., mortality or
incidence of HIV infection).
The internal validity of the studies included in the sys-
tematic review was assessed in 71 (72%) of the reviews;
53 (91%) of the Cochrane reviews and 18 (44%) of the
non-Cochrane reviews. Most reviews provided a narra-
tive discussion of the assessment of internal validity of
the trials included but did not specifically analyze the
assessments of internal validity in the analysis.
Data related to applicability of results
The reporting of applicability data for each study
included in the systematic reviews is described in
Table 2. The setting was systematically considered in
45 (46%) of the reviews, the number of centres in 21
(21%) and the country where the trial took place in 62
(63%).
Inclusion criteria for each included study were consid-
ered in 16 (16%) reviews (23% for Cochrane and 7% for
non-Cochrane reviews) and exclusion criteria in 13
(13%) (19% for Cochrane and 5% for non-Cochrane
reviews). Baseline characteristics of participants were
described in 59 (60%) of the reviews, with important
data such as age, sex, ethnicity, and socioeconomic sta-
tus frequently missing. Important criteria to reproduce
the intervention, such as treatment duration, dosage or
intensity, delivery format, and timing were missing in
one-quarter to one-half of the reviews. Information
related to care providers’ qualifications and specific
training were reported in 7 (7%) and 2 (2%) reviews,
respectively. The primary outcomes of each included
study were systematically reported in 67 (68%) reviews,
length of follow-up was missing in 64 (65%) of the
Figure 1 Flow diagram of the selected systematic reviews.
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reviews. The reporting of some of these data (setting,
number of centres, method of recruitment, baseline
characteristics, delivery format of treatment and primary
outcome) was better for Cochrane reviews than for non-
Cochrane reviews. For example, in a systematic review
on acupuncture and related interventions for smoking
cessation[36], the authors gave a description of all trials
included in the review in a table, indicating for each
trial (if it was reported in the primary trial) the country
where the trial took place, the mode of recruitment,
patients’ eligibility criteria, and details of the interven-
tion (number of sessions, duration of each session, acu-
puncture points etc.).
To evaluate the influence of applicability criteria, ana-
lyses were stratified by centre, country or setting in 6
(6%) systematic reviews, by components of intervention
in 41 (42%) reviews and by characteristics of participants
in 7 (7%) systematic reviews. Applicability was discussed
in the discussion section of 13 (13%) reviews.
Discussion
This study assessed the methods and reporting of infor-
mation on the applicability of trial results in systematic
reviews that might aid in applying their results. We
assessed 98 systematic reviews of research into interven-
tions aimed at reducing or stopping tobacco use and
treating or preventing HIV infection published during a
recent 10-year period. The applicability of results was
poorly reported and taken into account in these sys-
tematic reviews.
These results and our finding of lack of information
on cultural and socioeconomic contexts, patient charac-
teristics, and the content of the interventions in the
reviews questions how decision makers and clinicians
can use the results of such reviews [16,19,29,37-39]?
This situation is particularly problematic in the fields we
studied because more than half of the interventions con-
cerned nonpharmacologic treatments such as beha-
vioural interventions, which are complex and difficult to
reproduce in clinical practice, and the socioeconomic
Table 1 Characteristics of the selected systematic reviews
All reviews
N=9 8
Cochrane
reviews N = 57
Non-Cochrane
reviews N = 41
Tobacco use
N=4 9
HIV infection
N=4 9
Type of treatment, N (%)
Pharmacological treatment 33 (34) 23 (40) 10 (24) 17 (35) 16 (33)
Nonpharmacological treatment 59 (60) 28 (49) 31 (76) 28 (57) 31 (63)
Both treatments 6 (6) 6 (10) 0 4 (8) 2 (4)
Therapist-dependent intervention, N (%) 45 (46) 25 (44) 20 (49) 23 (47) 22 (45)
Method of the review, N (%)
Quantitative analysis 79 (81) 44 (77) 35 (85) 40 (82) 39 (79.6)
Number of studies included, median (Q1-Q3) 14 (7-25) 9 (5-21) 18 (12-27) 14 (7-26) 14 (7-20)
Trial design, N (%)
Randomised controlled trials (RCTs) only 68 (69) 46 (81) 22 (54) 42 (86) 26 (53)
RCTs + nonrandomized trials 24 (24) 8 (14) 16 (39) 5 (10) 19 (39)
Nonrandomized trials only 6 (6) 3 (5) 3 (7) 2 (4) 4 (8)
Reporting of key data to describe included studies
in a table or figure, N (%)
87 (88) 53 (93) 33 (88) 40 (82) 46 (94)
Internal validity assessment, N (%) 71 (72) 53 (91) 18 (44) 35 (86) 36 (73)
Quality score 11 (11) 1 (2) 10 (24) 10 (20) 1 (2)
Allocation sequence generation 44 (52) 37 (65) 7 (17) 30 (61) 14 (29)
Allocation concealment 59 (58) 51 (89) 8 (19) 31 (63) 28 (57)
Blinding of participants 21 (21) 17 (30) 4 (10) 6 (12) 15 (31)
Blinding of care providers 22 (22) 18 (32) 4 (10) 5 (10) 17 (35)
Blinding of outcome assessors 10 (10) 6 (10) 4 (15) 4 (12) 6 (12)
Intent-to-treat analysis 13 (13) 8 (14) 5 (12) 5 (10) 8 (16)
Method to account for internal validity, N (%)
Sensitivity analysis 8 (8) 3 (5) 5 (12) 4 (8) 4 (8)
Weighting factor 0 0 0 0 0
Meta regression 0 0 0 0 0
Narrative discussion of internal validity 52 (52) 48 (84) 4 (10) 23 (47) 26 (53)
Q1-Q3 = interquartile range 1 to 3
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clinical practice.
Considering that applicability is essential for the devel-
opers of guidelines to grade the strength of recommen-
dations, the Grading of Recommendations Assessment,
Development and Evaluation (GRADE) system for grad-
ing the evidence of clinical guidelines clearly tackles this
issue [40].
This grading system separates decisions regarding the
quality of evidence (mainly considering the internal
validity of the studies) from strength of recommenda-
tions (i.e., taking into account the risk-benefit balance).
The strength of the recommendations are likely to differ
by practice settings or patient group[41]. For example,
in the field of cardiovascular risk management,
randomized controlled trial-based evidence was down-
graded most often because of reservations about the
applicability of the trial results[42].
Most of the effort of methodological research in the
field of systematic reviews, particularly the work by the
Cochrane Collaboration, has focused on the evaluation
of internal validity. The results of these efforts empha-
size a better consideration of internal validity in sys-
tematic reviews performed by the Cochrane
Collaboration [43,44]. However, evaluating applicability
of results is of similar importance. In the field of HIV
interventions for example, Merson et al. highlighted “the
lack of [...] contextual data to tailor specific interven-
tions is reprehensible, particularly in view of the large
amount of resources that have been invested to date in
Table 2 Data related to applicability of results systematically reported for trials included in the systematic reviews
All reviews N = 98 Cochrane reviews
N=5 7
Non-Cochrane
reviews N = 41
Tobacco use
N=4 9
HIV infection
N=4 9
Setting and centres
Setting of recruitment 45 (46) 33 (58) 12 (29) 24 (49) 21 (43)
Number of centres 21 (21) 19 (33) 2 (5) 15 (31) 6 (12)
Country where the study took
place
62 (63) 41 (72) 21 (51) 29 (59) 33 (67)
Recruitment
Method 18 (18) 18 (32) 0 15 (31) 3 (6)
Participants
Inclusion criteria 16 (16) 13 (23) 3 (7) 5 (10) 11 (22)
Exclusion criteria 13 (13) 11 (19) 2 (5) 4 (8) 9 (18)
Baseline characteristics of
participants
59 (60) 42 (74) 17 (41) 29 (59) 30 (61)
Age 47 (48) 35 (61) 12 (29) 26 (53) 21 (43)
Mean or median only 39 (40) 29 (51) 10 (24) 21 (43) 18 (37)
Mean (SD) or median
(IQR)
3 (3) 3 (5) 0 0 3 (6)
Minimum and
maximum value only
17 (17) 12 (21) 5 (12) 8 (16) 9 (18)
Sex 46 (47) 33 (58) 13 (32) 22 (45) 24 (49)
Ethnicity 9 (9) 4 (3) 5 (12) 2 (4) 7 (14)
Socioeconomic status 1 (1) 1 (2.0) 0 0 1 (2)
Co-morbidities 0 0 0 0 0
Associated treatments 0 0 0 0 0
Treatment
Duration of treatment 61 (62) 40 (70) 21 (51) 35 (71) 26 (53)
Intensity/dose of treatment 64 (65) 44 (77) 20 (49) 34 (69) 30 (61)
Delivery format of treatment 72 (73) 49 (86) 23 (56) 37 (75) 35 (71)
Treatment timing 52 (53) 40 (70) 12 (29) 30 (61) 22 (45)
Compliance of participants 3 (3) 0 3 (7) 0 3 (6)
Outcome assessment
Primary outcome 67 (68) 52 (91) 15 (37) 22 (45) 35 (71)
Adverse events 5 (5) 3 (5) 2 (5) 2 (4) 3 (6)
Follow up
Length of follow-up 34 (35) 17 (30) 17 (41) 20 (41) 14 (29)
Number of visits 13 (13) 12 (21) 1 (2) 9 (18) 4 (8)
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ity to make informed decisions on prevention priori-
ties”[45]. The Applicability and Recommendations
Methods Group (ARMG) of the Cochrane Collaboration
is nevertheless tackling this important but difficult issue,
and recommendations are pending. To add to this dis-
cussion, from our results, we propose 3 recommenda-
tions for performing systematic reviews and 3
recommendations for methodological research (see
Additional file 3).
Assessing applicability and external validity is difficult
[4]. As well, deciding which items are relevant and
should be reported is difficult. Further, the importance
of some items may vary by context (e.g., assessing phar-
macologic treatments or nonpharmacologic treatments).
Therefore, when planning a systematic review, the pro-
tocol should define which applicability items are impor-
tant and should be collected and reported. Not all of the
applicability items we evaluated necessarily interact with
effect size. However, methodological work evaluating
the impact of applicability on effect size is lacking, and
therefore, making a definitive statement on this issue is
difficult. Further, even if some applicability items do not
interact with effect size, details of applicability items
must be provided to allow clinicians, patients and deci-
sion makers decide whether and how they will apply the
results in clinical practice. Ite m si d e n t i f i e da sp o s s i b l y
interacting with treatment effect estimates should be
offered as a priori explanations of heterogeneity, and an
exploration of whether treatment differs across these
characteristics should be undertaken. Other items aimed
at helping readers appraise the applicability of the trials
in their context should be reported. Online addenda
now provide a great opportunity to adequately describe
the included studies for interested readers without bur-
dening every reader.
The reporting of data related to external validity is
now clearly indicated in the PRISMA statement for
reporting systematic reviews and meta-analyses. The
PRISMA statement clearly focuses on the need to con-
sider components to frame the question known by the
acronym “PICOS” (Patient, Intervention, Comparator
group, Outcome, and Study design). Focusing on
PICOS, the statement should improve the reporting of
external validity. In fact, issues related to PICOS affect
several PRISMA items with the need to clearly describe
participants, the disease, the setting of care, the inter-
vention, and the comparator.
One explanation for the differences between Cochrane
and non-Cochrane reviews could be linked to the space
constraints (limited word count, number of tables and
figures) requested by some editors but not by publishers
of Cochrane Library reports. Further, the question eval-
uated in Cochrane and non-Cochrane reviews differed
in terms of the type of treatment (pharmacologic or
nonpharmacologic); for example, about half of the
Cochrane reviews evaluated drugs, whereas non-
Cochrane reviews more often evaluated nonpharmacolo-
gical treatments
This study has several limitations. First, we focused on
two medical areas, and these results should be confirmed
in other medical areas. However, we chose tobacco con-
sumption and HIV infection because they are among the
first 5 causes of mortality in the world. Second, currently
no consensus exists on how to assess the applicability of
study results, we identified the applicability items follow-
ing a literature review, and the relevance of some items
might vary. Third, we did not consider the importance of
each item even though it may vary according to context
(e.g., assessing pharmacologic treatments or nonpharma-
cologic treatments). Fourth, during the appraisal process,
we assumed that if data were reported in at least one ran-
domized controlled trial included on the systematic
review, this data had been gathered systematically in the
systematic review. This assumption may have overesti-
mated the reporting. Fifth, we excluded systematic reviews
of reports for specific contexts or a specific population,
which may have biased our sample of reviews to those
widely applicable.
Finally, the screening process and the data collection
were performed by only one reviewer. However, a qual-
ity assurance procedure was performed.
Conclusions
In conclusion, despite the large number of systematic
reviews published, our study highlights the lack of con-
sideration of data related to the applicability and gener-
alisability of results in these reviews.
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